Open AccessSUN-LB064 A Phase 2, Dose-Escalation, Safety and Efficacy Study of Tildacerfont (SPR001) for the Treatment of Patients with Classic Congenital Adrenal Hyperplasia
Author(s) -
Kyriakie Sarafoglou,
Ron S. Newfield,
Maria Vogiatzi,
Erik A. Imel,
A. Ola Odugbesan,
Ivy-Joan Madu,
Samer Nakhle,
Alexis Howerton,
Michael Huang,
Kelly Vandever,
Rong Lin,
Alyssa Wu-Zhang,
Richard J. Auchus
Publication year - 2019
Publication title -
journal of the endocrine society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.046
H-Index - 20
ISSN - 2472-1972
DOI - 10.1210/js.2019-sun-lb064
Subject(s) - congenital adrenal hyperplasia , medicine , cohort , adverse effect , androgen , endocrinology , adrenocorticotropic hormone , regimen , pharmacodynamics , dosing , glucocorticoid , androgen excess , pharmacokinetics , gastroenterology , hormone , insulin resistance , polycystic ovary , insulin